Chimpanzee-origin adenovirus vectors as vaccine carriers
Open Access
- 1 December 2005
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 13 (5) , 421-429
- https://doi.org/10.1038/sj.gt.3302675
Abstract
Vaccines based on replication-defective adenoviral vectors are being developed for infectious agents and tumor-associated antigens. Early work focused on vaccines derived from a common human serotype of adenovirus, that is, adenovirus of the serotype 5 (AdHu5). Neutralizing antibodies against AdHu5 virus, present in a large percentage of the human population, dampen the efficacy of vaccines based on this carrier. To circumvent this problem, we generated vectors derived from chimpanzee adenoviruses. Here we describe some basic parameters of vectors derived from chimpanzee adenoviruses C68 and C7, including growth characteristics, yields of infectious particles, effects of additional deletions in E3 and E4 and lengths of the inserted foreign sequence as they relate to the suitability for their eventual development as vaccine carriers for clinical use.Keywords
This publication has 34 references indexed in Scilit:
- Adenovirus Vector-Based Vaccines for Human Immunodeficiency Virus Type 1Human Gene Therapy, 2005
- Adenoviruses as vaccine vectorsMolecular Therapy, 2004
- Characterization of a Family of Chimpanzee Adenoviruses and Development of Molecular Clones for Gene Transfer VectorsHuman Gene Therapy, 2004
- Novel, Chimpanzee Serotype 68-Based Adenoviral Vaccine Carrier for Induction of Antibodies to a Transgene ProductJournal of Virology, 2002
- Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunityNature, 2002
- Replication-Defective Vector Based on a Chimpanzee AdenovirusJournal of Virology, 2001
- A Novel Recombinant Adeno-Associated Virus Vaccine Induces a Long-Term Humoral Immune Response to Human Immunodeficiency VirusHuman Gene Therapy, 2001
- Differential influence of the E4 adenoviral genes on viral and cellular promotersThe Journal of Gene Medicine, 2000
- Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacementGene Therapy, 1999
- Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5Journal of General Virology, 1977